Business Context and Reporting Period
Company: OraSure Technologies, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 30, 2021 (Event Date); October 4, 2021 (Filing Date)
Context: The Company entered into a material definitive agreement with the U.S. Department of Defense (DOD) to expand manufacturing capacity for its InteliSwab COVID-19 rapid tests.
Key Financial Metrics
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data point disclosed is the value of a new funding agreement.
- Funding Amount: $109 million
- Funding Source: U.S. Department of Defense (in coordination with the Department of Health and Human Services)
- Production Capacity Expansion: 100 million tests annually
Material Changes
The material change reported is the execution of a government funding agreement on September 30, 2021. This agreement is designed to support the nation's pandemic preparedness plan by increasing domestic manufacturing capabilities. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
Management Commentary and Outlook:
- Funding will be disbursed based on the achievement of specific milestones through March 2024.
- Milestones include the design, acquisition, installation, qualification, and acceptance of manufacturing equipment.
- Implementation involves retrofitting an existing facility in Bethlehem, PA, and adding a new facility at an undetermined U.S. location.
- Termination for Cause: The DOD may terminate the agreement if the Company defaults, fails to comply with terms, or fails to provide adequate assurance of future performance.
- Termination for Convenience: The DOD retains the right to terminate the agreement, or any part thereof, for its sole convenience.
- Asset Vesting: Title to equipment and property vests in the Company only upon completion of requirements or in the event of termination.
The funding is contingent on milestone achievement rather than an immediate lump-sum payment, and the specific location for the new facility has not yet been determined.
Investor Verification Checklist
- Verify the specific milestones required to trigger funding payments through March 2024.
- Confirm the timeline and location for the new manufacturing facility.
- Review the full text of the Agreement (filed as an exhibit to the Form 10-Q for the quarter ended September 30, 2021) for detailed termination clauses.
- Monitor future 10-Q filings for the recognition of revenue or grant income associated with this agreement.